research

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Authors
    Publication date
    4 November 2015
    Publisher
    BioMed Central
    Doi

      Abstract

      Abstract is not available.

        Similar works

        Full text

        thumbnail-image

        Available Versions

        Springer - Publisher Connector

        redirect
        Last time updated on 28/04/2017